Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(9):646-647; doi:10.1093/jnci/90.9.646
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nelson, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, N. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Anti-Estrogens Come of Age: A Pioneer Looks Back

"Within the next 2 years, it will be routine to prevent breast cancer in the postmenopausal population," predicted V. Craig Jordan, Ph.D., of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago.

Not long ago Jordan's statement -- made in New Orleans, at the American Association for Cancer Research in late March -- may have seemed a bit far-fetched. But the recent early release of the results from the tamoxifen prevention trial (see next page) makes Jordan's prediction more credible. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?